schliessen

Filtern

 

Bibliotheken

Major benefits from cholesterol-lowering in patients with diabetes

Two other recent randomised statin trials involving large numbers of patients with type 2 diabetes did not show any significant difference when active therapy was compared with either usual care or placebo treatment. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial... Full description

Journal Title: The Lancet (British edition) 2003, Vol.361 (9374), p.2000-2001
Main Author: Lindholm, Lars H
Format: Electronic Article Electronic Article
Language: English
Subjects:
Quelle: Alma/SFX Local Collection
Publisher: England: Elsevier Ltd
ID: ISSN: 0140-6736
Link: https://www.ncbi.nlm.nih.gov/pubmed/12814705
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_proquest_miscellaneous_73395414
title: Major benefits from cholesterol-lowering in patients with diabetes
format: Article
creator:
  • Lindholm, Lars H
subjects:
  • Abridged Index Medicus
  • Anticholesteremic Agents - therapeutic use
  • Cardiovascular Diseases - etiology
  • Cardiovascular Diseases - prevention & control
  • Care and treatment
  • Cholesterol
  • Clinical trials
  • Complications
  • Diabetes
  • Diabetes Mellitus, Type 1 - complications
  • Diabetes Mellitus, Type 2 - complications
  • Drug therapy
  • Evaluation
  • Humans
  • Statins
  • Type 2 diabetes
ispartof: The Lancet (British edition), 2003, Vol.361 (9374), p.2000-2001
description: Two other recent randomised statin trials involving large numbers of patients with type 2 diabetes did not show any significant difference when active therapy was compared with either usual care or placebo treatment. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT),1 40 mg pravastatin daily was compared with usual care in more than 10 000 hypertensive patients (mean age 66 years). About 3600 had type 2 diabetes at randomisation. Mainly due to the use of non-study statin therapy in the usual-care group, the average difference in LDL-cholesterol concentration between these two treatment groups was only about 0[middot]6 mmol/L during 4[middot]8 years' follow-up, and there was no significant difference in the all-cause mortality or coronary event rates, with or without the presence of type 2 diabetes at baseline. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA),2 10 mg atorvastatin daily was compared with placebo in more than 10 000 hypertensive patients (mean age 63 years), of whom about 2500 had type 2 diabetes at entry. The average difference in LDL-cholesterol concentration between the groups was about 1[middot]1 mmol/L during 3[middot]3 years' follow-up. In the patients with diabetes, there was no significant difference (p=0[middot]43) between the incidence of primary events (non-fatal myocardial infarction and fatal coronary heart disease)-3[middot]0% atorvastatin compared with 3[middot]6% placebo.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0140-6736
fulltext: fulltext
issn:
  • 0140-6736
  • 1474-547X
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK1.984868
LOCALfalse
PrimoNMBib
record
control
sourceidgale_proqu
recordidTN_cdi_proquest_miscellaneous_73395414
sourceformatXML
sourcesystemPC
galeidA103410621
sourcerecordidA103410621
originalsourceidFETCH-LOGICAL-c483t-19dead38506f09bd537107c072ea6424da7b205ae542ef7697950941f9b4a4523
addsrcrecordideNqFkV1rFDEUhoNY7Hb1JyiDQrHg1JNJMtnghdTiF1S8UMG7kMmc2c0yM1mTTEv_vdnuorYIJZCE8JyXc_IQ8pTCKQVav_4GlENZS1a_BHZCWS2rEh6QGeWSl4LLnw_J7A9ySI5iXAMAr0E8Ioe0WmQOxIy8-2LWPhQNjti5FIsu-KGwK99jTBh8X_b-CoMbl4Ubi41JDsdMXbm0KlpnGkwYH5ODzvQRn-zPOfnx4f3380_lxdePn8_PLkrLFyyVVLVoWrYQUHegmlYwSUFakBWamle8NbKpQBgUvMJO1koqAYrTTjXccFGxOTne5W6C_zXl_vTgosW-NyP6KWrJmBKc8gw-vwOu_RTG3JumSgEHqhYZerGDlqZH7cbOp2DsNlGfUWCcQl3RTJ3-h8qrxcFZv_20_H6r4NU_Bc0U3Ygxb9EtVykuzRTjbVzscBt8jAE7vQluMOFaU9Bbz_rGs95K1MD0jed8mZNn-xGnZsD2b9VebAbe3Am2LmV9fswDuP7e-Le7asw-Lx0GHW02b7F1AW3SrXf3JPwGJDXGXg
sourcetypeAggregation Database
isCDItrue
recordtypearticle
pqid199040198
display
typearticle
titleMajor benefits from cholesterol-lowering in patients with diabetes
sourceAlma/SFX Local Collection
creatorLindholm, Lars H
creatorcontribLindholm, Lars H
descriptionTwo other recent randomised statin trials involving large numbers of patients with type 2 diabetes did not show any significant difference when active therapy was compared with either usual care or placebo treatment. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT),1 40 mg pravastatin daily was compared with usual care in more than 10 000 hypertensive patients (mean age 66 years). About 3600 had type 2 diabetes at randomisation. Mainly due to the use of non-study statin therapy in the usual-care group, the average difference in LDL-cholesterol concentration between these two treatment groups was only about 0[middot]6 mmol/L during 4[middot]8 years' follow-up, and there was no significant difference in the all-cause mortality or coronary event rates, with or without the presence of type 2 diabetes at baseline. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA),2 10 mg atorvastatin daily was compared with placebo in more than 10 000 hypertensive patients (mean age 63 years), of whom about 2500 had type 2 diabetes at entry. The average difference in LDL-cholesterol concentration between the groups was about 1[middot]1 mmol/L during 3[middot]3 years' follow-up. In the patients with diabetes, there was no significant difference (p=0[middot]43) between the incidence of primary events (non-fatal myocardial infarction and fatal coronary heart disease)-3[middot]0% atorvastatin compared with 3[middot]6% placebo.
identifier
0ISSN: 0140-6736
1EISSN: 1474-547X
2DOI: 10.1016/S0140-6736(03)13672-0
3PMID: 12814705
4CODEN: LANCAO
languageeng
publisherEngland: Elsevier Ltd
subjectAbridged Index Medicus ; Anticholesteremic Agents - therapeutic use ; Cardiovascular Diseases - etiology ; Cardiovascular Diseases - prevention & control ; Care and treatment ; Cholesterol ; Clinical trials ; Complications ; Diabetes ; Diabetes Mellitus, Type 1 - complications ; Diabetes Mellitus, Type 2 - complications ; Drug therapy ; Evaluation ; Humans ; Statins ; Type 2 diabetes
ispartofThe Lancet (British edition), 2003, Vol.361 (9374), p.2000-2001
rights
02003 Elsevier Ltd
1Copyright Lancet Ltd. Jun 14, 2003
lds50peer_reviewed
citedbyFETCH-LOGICAL-c483t-19dead38506f09bd537107c072ea6424da7b205ae542ef7697950941f9b4a4523
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12814705$$D View this record in MEDLINE/PubMed
search
creatorcontribLindholm, Lars H
title
0Major benefits from cholesterol-lowering in patients with diabetes
1The Lancet (British edition)
addtitleLancet
descriptionTwo other recent randomised statin trials involving large numbers of patients with type 2 diabetes did not show any significant difference when active therapy was compared with either usual care or placebo treatment. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT),1 40 mg pravastatin daily was compared with usual care in more than 10 000 hypertensive patients (mean age 66 years). About 3600 had type 2 diabetes at randomisation. Mainly due to the use of non-study statin therapy in the usual-care group, the average difference in LDL-cholesterol concentration between these two treatment groups was only about 0[middot]6 mmol/L during 4[middot]8 years' follow-up, and there was no significant difference in the all-cause mortality or coronary event rates, with or without the presence of type 2 diabetes at baseline. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA),2 10 mg atorvastatin daily was compared with placebo in more than 10 000 hypertensive patients (mean age 63 years), of whom about 2500 had type 2 diabetes at entry. The average difference in LDL-cholesterol concentration between the groups was about 1[middot]1 mmol/L during 3[middot]3 years' follow-up. In the patients with diabetes, there was no significant difference (p=0[middot]43) between the incidence of primary events (non-fatal myocardial infarction and fatal coronary heart disease)-3[middot]0% atorvastatin compared with 3[middot]6% placebo.
subject
0Abridged Index Medicus
1Anticholesteremic Agents - therapeutic use
2Cardiovascular Diseases - etiology
3Cardiovascular Diseases - prevention & control
4Care and treatment
5Cholesterol
6Clinical trials
7Complications
8Diabetes
9Diabetes Mellitus, Type 1 - complications
10Diabetes Mellitus, Type 2 - complications
11Drug therapy
12Evaluation
13Humans
14Statins
15Type 2 diabetes
issn
00140-6736
11474-547X
fulltexttrue
rsrctypearticle
creationdate2003
recordtypearticle
recordideNqFkV1rFDEUhoNY7Hb1JyiDQrHg1JNJMtnghdTiF1S8UMG7kMmc2c0yM1mTTEv_vdnuorYIJZCE8JyXc_IQ8pTCKQVav_4GlENZS1a_BHZCWS2rEh6QGeWSl4LLnw_J7A9ySI5iXAMAr0E8Ioe0WmQOxIy8-2LWPhQNjti5FIsu-KGwK99jTBh8X_b-CoMbl4Ubi41JDsdMXbm0KlpnGkwYH5ODzvQRn-zPOfnx4f3380_lxdePn8_PLkrLFyyVVLVoWrYQUHegmlYwSUFakBWamle8NbKpQBgUvMJO1koqAYrTTjXccFGxOTne5W6C_zXl_vTgosW-NyP6KWrJmBKc8gw-vwOu_RTG3JumSgEHqhYZerGDlqZH7cbOp2DsNlGfUWCcQl3RTJ3-h8qrxcFZv_20_H6r4NU_Bc0U3Ygxb9EtVykuzRTjbVzscBt8jAE7vQluMOFaU9Bbz_rGs95K1MD0jed8mZNn-xGnZsD2b9VebAbe3Am2LmV9fswDuP7e-Le7asw-Lx0GHW02b7F1AW3SrXf3JPwGJDXGXg
startdate2003
enddate2003
creatorLindholm, Lars H
general
0Elsevier Ltd
1Elsevier B.V
2Elsevier Limited
scope
0CGR
1CUY
2CVF
3ECM
4EIF
5NPM
6AAYXX
7CITATION
8BSHEE
90TT
100TZ
110U~
123V.
137QL
147QP
157RV
167TK
177U7
187U9
197X7
207XB
2188A
2288C
2388E
2488G
2588I
268AF
278AO
288C1
298C2
308FE
318FH
328FI
338FJ
348FK
358G5
36ABUWG
37AN0
38ASE
39AZQEC
40BBNVY
41BEC
42BENPR
43BHPHI
44C1K
45DWQXO
46FPQ
47FYUFA
48GHDGH
49GNUQQ
50GUQSH
51H94
52HCIFZ
53K6X
54K9-
55K9.
56KB0
57KB~
58LK8
59M0R
60M0S
61M0T
62M1P
63M2M
64M2O
65M2P
66M7N
67M7P
68MBDVC
69NAPCQ
70PQEST
71PQQKQ
72PQUKI
73Q9U
74S0X
757X8
sort
creationdate2003
titleMajor benefits from cholesterol-lowering in patients with diabetes
authorLindholm, Lars H
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c483t-19dead38506f09bd537107c072ea6424da7b205ae542ef7697950941f9b4a4523
rsrctypearticles
prefilterarticles
languageeng
creationdate2003
topic
0Abridged Index Medicus
1Anticholesteremic Agents - therapeutic use
2Cardiovascular Diseases - etiology
3Cardiovascular Diseases - prevention & control
4Care and treatment
5Cholesterol
6Clinical trials
7Complications
8Diabetes
9Diabetes Mellitus, Type 1 - complications
10Diabetes Mellitus, Type 2 - complications
11Drug therapy
12Evaluation
13Humans
14Statins
15Type 2 diabetes
toplevel
0peer_reviewed
1online_resources
creatorcontribLindholm, Lars H
collection
0Medline
1MEDLINE
2MEDLINE (Ovid)
3MEDLINE
4MEDLINE
5PubMed
6CrossRef
7Academic OneFile (A&I only)
8News PRO
9Pharma and Biotech Premium PRO
10Global News & ABI/Inform Professional
11ProQuest Central (Corporate)
12Bacteriology Abstracts (Microbiology B)
13Calcium & Calcified Tissue Abstracts
14Nursing & Allied Health Database
15Neurosciences Abstracts
16Toxicology Abstracts
17Virology and AIDS Abstracts
18Health & Medical Collection
19ProQuest Central (purchase pre-March 2016)
20Biology Database (Alumni Edition)
21Healthcare Administration Database (Alumni)
22Medical Database (Alumni Edition)
23Psychology Database (Alumni)
24Science Database (Alumni Edition)
25STEM Database
26ProQuest Pharma Collection
27Public Health Database
28Lancet Titles
29ProQuest SciTech Collection
30ProQuest Natural Science Collection
31Hospital Premium Collection
32Hospital Premium Collection (Alumni Edition)
33ProQuest Central (Alumni) (purchase pre-March 2016)
34Research Library (Alumni Edition)
35ProQuest Central (Alumni Edition)
36British Nursing Database
37British Nursing Index
38ProQuest Central Essentials
39Biological Science Collection
40eLibrary
41ProQuest Central
42Natural Science Collection
43Environmental Sciences and Pollution Management
44ProQuest Central Korea
45British Nursing Index (BNI) (1985 to Present)
46Health Research Premium Collection
47Health Research Premium Collection (Alumni)
48ProQuest Central Student
49Research Library Prep
50AIDS and Cancer Research Abstracts
51SciTech Premium Collection
52British Nursing Index
53Consumer Health Database (Alumni Edition)
54ProQuest Health & Medical Complete (Alumni)
55Nursing & Allied Health Database (Alumni Edition)
56ProQuest Newsstand Professional
57ProQuest Biological Science Collection
58Consumer Health Database
59Health & Medical Collection (Alumni Edition)
60Healthcare Administration Database
61Medical Database
62Psychology Database
63Research Library
64Science Database
65Algology Mycology and Protozoology Abstracts (Microbiology C)
66Biological Science Database
67Research Library (Corporate)
68Nursing & Allied Health Premium
69ProQuest One Academic Eastern Edition
70ProQuest One Academic
71ProQuest One Academic UKI Edition
72ProQuest Central Basic
73SIRS Editorial
74MEDLINE - Academic
jtitleThe Lancet (British edition)
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
auLindholm, Lars H
formatjournal
genrearticle
ristypeJOUR
atitleMajor benefits from cholesterol-lowering in patients with diabetes
jtitleThe Lancet (British edition)
addtitleLancet
date2003
risdate2003
volume361
issue9374
spage2000
epage2001
pages2000-2001
issn0140-6736
eissn1474-547X
codenLANCAO
abstractTwo other recent randomised statin trials involving large numbers of patients with type 2 diabetes did not show any significant difference when active therapy was compared with either usual care or placebo treatment. In the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT),1 40 mg pravastatin daily was compared with usual care in more than 10 000 hypertensive patients (mean age 66 years). About 3600 had type 2 diabetes at randomisation. Mainly due to the use of non-study statin therapy in the usual-care group, the average difference in LDL-cholesterol concentration between these two treatment groups was only about 0[middot]6 mmol/L during 4[middot]8 years' follow-up, and there was no significant difference in the all-cause mortality or coronary event rates, with or without the presence of type 2 diabetes at baseline. In the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT-LLA),2 10 mg atorvastatin daily was compared with placebo in more than 10 000 hypertensive patients (mean age 63 years), of whom about 2500 had type 2 diabetes at entry. The average difference in LDL-cholesterol concentration between the groups was about 1[middot]1 mmol/L during 3[middot]3 years' follow-up. In the patients with diabetes, there was no significant difference (p=0[middot]43) between the incidence of primary events (non-fatal myocardial infarction and fatal coronary heart disease)-3[middot]0% atorvastatin compared with 3[middot]6% placebo.
copEngland
pubElsevier Ltd
pmid12814705
doi10.1016/S0140-6736(03)13672-0